
## **Chris Stockmann**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5162132/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An Evaluation of Vancomycin Area Under the Curve Estimation Methods for Children Treated for Acute Pulmonary Exacerbations of Cystic Fibrosis Due to Methicillinâ€Resistant <i>Staphylococcus aureus</i> . Journal of Clinical Pharmacology, 2019, 59, 198-205.	1.0	15
2	Individualized Empiric Vancomycin Dosing in Neonates Using a Model-Based Approach. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 97-104.	0.6	34
3	Procalcitonin Accurately Identifies Hospitalized Children With Low Risk of Bacterial Community-Acquired Pneumonia. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 46-53.	0.6	89
4	Impact of Antimicrobial Stewardship for Pediatric Outpatient Parenteral Antibiotic Therapy. Journal of the Pediatric Infectious Diseases Society, 2018, 7, e34-e36.	0.6	27
5	Transmission of rhinovirus in the Utah BIG-LoVE families: Consequences of age and household structure. PLoS ONE, 2018, 13, e0199388.	1.1	11
6	Detection of 23 Gastrointestinal Pathogens Among Children Who Present With Diarrhea. Journal of the Pediatric Infectious Diseases Society, 2017, 6, piw020.	0.6	36
7	Limited and Variable Use of Antivirals for Children Hospitalized With Influenza. JAMA Pediatrics, 2017, 171, 299.	3.3	12
8	Inhaled Remimazolam Potentiates Inhaled Remifentanil in Rodents. Anesthesia and Analgesia, 2017, 124, 1484-1490.	1.1	14
9	Epidemiology of Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia in Children. Pediatrics, 2017, 139, .	1.0	42
10	Predicting tacrolimus concentrations in children receiving a heart transplant using a population pharmacokinetic model. BMJ Paediatrics Open, 2017, 1, e000147.	0.6	11
11	Clinical Predictors of Shigella and Campylobacter Infection in Children in the United States. Open Forum Infectious Diseases, 2017, 4, S362-S362.	0.4	0
12	Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials. Current Clinical Pharmacology, 2016, 11, 53-61.	0.2	21
13	Laboratory-Confirmed Human Coronavirus Infections Among Children: Does Type Matter?. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
14	Impact of Antimicrobial Stewardship Review for Pediatric Outpatient Parenteral Antimicrobial Therapy (OPAT). Open Forum Infectious Diseases, 2016, 3, .	0.4	0
15	Unanswered Questions Regarding Optimal Pediatric Vancomycin Use. Therapeutic Drug Monitoring, 2016, 38, 419-420.	1.0	2
16	Inhaled Remifentanil in Rodents. Anesthesia and Analgesia, 2016, 122, 1831-1838.	1.1	8
17	Renal Function Descriptors in Neonates: Which Creatinineâ€Based Formula Best Describes Vancomycin Clearance?. Journal of Clinical Pharmacology, 2016, 56, 528-540.	1.0	8
18	Pregnancyâ€induced changes in the pharmacokinetics of caffeine and its metabolites. Journal of Clinical Pharmacology, 2016, 56, 590-596.	1.0	45

#	Article	IF	CITATIONS
19	Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parent–Metabolite Population Pharmacokinetic Model. Clinical Pharmacokinetics, 2016, 55, 1395-1411.	1.6	37
20	A Retrospective Study of the Impact of Rapid Diagnostic Testing on Time to Pathogen Identification and Antibiotic Use for Children with Positive Blood Cultures. Infectious Diseases and Therapy, 2016, 5, 555-570.	1.8	15
21	Characterization of Transient Receptor Potential Vanilloid-1 (TRPV1) Variant Activation by Coal Fly Ash Particles and Associations with Altered Transient Receptor Potential Ankyrin-1 (TRPA1) Expression and Asthma. Journal of Biological Chemistry, 2016, 291, 24866-24879.	1.6	31
22	Taxonomer: an interactive metagenomics analysis portal for universal pathogen detection and host mRNA expression profiling. Genome Biology, 2016, 17, 111.	3.8	152
23	Clinical and Epidemiological Evidence of the Red Queen Hypothesis in Pneumococcal Serotype Dynamics. Clinical Infectious Diseases, 2016, 63, 619-626.	2.9	19
24	Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections. Expert Review of Anti-Infective Therapy, 2016, 14, 731-746.	2.0	20
25	Therapeutic Drug Monitoring of Ganciclovir Treatment for Cytomegalovirus Infections Among Immunocompromised Children. Journal of the Pediatric Infectious Diseases Society, 2016, 5, 231-232.	0.6	14
26	Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children. Vaccine, 2016, 34, 474-478.	1.7	17
27	Ventilator-Associated Pneumonia in Pediatric Traumatic Brain Injury. Journal of Neurotrauma, 2016, 33, 832-839.	1.7	20
28	A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2016, 101, F236-F243.	1.4	32
29	Population Pharmacokinetics of Intravenous Paracetamol (Acetaminophen) in Preterm and Term Neonates: Model Development and External Evaluation. Clinical Pharmacokinetics, 2016, 55, 107-119.	1.6	42
30	Incidence, Morbidity, and Costs of Human Metapneumovirus Infection in Hospitalized Children. Journal of the Pediatric Infectious Diseases Society, 2016, 5, 303-311.	0.6	31
31	A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults. Clinical Drug Investigation, 2015, 35, 633-643.	1.1	5
32	National Trends in the Incidence, Outcomes and Charges of Pediatric Osteoarticular Infections, 1997–2012. Pediatric Infectious Disease Journal, 2015, 34, 672-674.	1.1	23
33	Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis. Journal of Burn Care and Research, 2015, 36, e244-e252.	0.2	27
34	Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration–Time Curve to the Minimum Inhibitory Concentration ≥400 Target. Therapeutic Drug Monitoring, 2015, 37, 756-765.	1.0	21
35	Economic Analysis of Rapid and Sensitive Polymerase Chain Reaction Testing in the Emergency Department for Influenza Infections in Children. Pediatric Infectious Disease Journal, 2015, 34, 577-582.	1.1	50
36	Clinical Pharmacokinetics of Inhaled Antimicrobials. Clinical Pharmacokinetics, 2015, 54, 473-492.	1.6	20

#	Article	IF	CITATIONS
37	Activation of Transient Receptor Potential Ankyrin-1 by Insoluble Particulate Material and Association with Asthma. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 893-901.	1.4	43
38	Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates. Infectious Diseases and Therapy, 2015, 4, 187-198.	1.8	55
39	Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. Pediatric Research, 2015, 78, 315-322.	1.1	42
40	Appropriate prescribing for acute childhood infections. Paediatrics and International Child Health, 2015, 35, 1-2.	0.3	0
41	Pharmacokinetic considerations in the use of antivirals in neonates. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1861-1878.	1.5	3
42	Quantitative Assay Validation for Oxandrolone in Human Plasma Using LC–MS-MS. Journal of Analytical Toxicology, 2015, 39, 526-531.	1.7	2
43	Comparative Effectiveness of Oral Versus Outpatient Parenteral Antibiotic Therapy for Empyema. Hospital Pediatrics, 2015, 5, 605-612.	0.6	20
44	Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 205-219.	1.5	32
45	Levofloxacin inhalation solution for the treatment of chronic <i>Pseudomonas aeruginosa</i> infection among patients with cystic fibrosis. Expert Review of Respiratory Medicine, 2015, 9, 13-22.	1.0	20
46	Optimal design in pediatric pharmacokinetic and pharmacodynamic clinical studies. Paediatric Anaesthesia, 2015, 25, 222-230.	0.6	25
47	Community-Acquired Pneumonia Requiring Hospitalization among U.S. Children. New England Journal of Medicine, 2015, 372, 835-845.	13.9	1,235
48	PCV13 in the USA: early successes and potential challenges. Lancet Infectious Diseases, The, 2015, 15, 254-256.	4.6	4
49	Effect of CYP3A5*3 on asthma control among children treated with inhaled beclomethasone. Journal of Allergy and Clinical Immunology, 2015, 136, 505-507.	1.5	12
50	Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy. Clinical Pharmacokinetics, 2015, 54, 1237-1244.	1.6	7
51	Application of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data. Biopharmaceutics and Drug Disposition, 2015, 36, 405-409.	1.1	0
52	Relationship Between Zolpidem Concentrations and Sleep Parameters in Pediatric Burn Patients. Journal of Burn Care and Research, 2015, 36, 137-144.	0.2	6
53	Outpatient Parenteral Antimicrobial Therapy in Pediatrics: An Opportunity to Expand Antimicrobial Stewardship. Infection Control and Hospital Epidemiology, 2015, 36, 222-224.	1.0	23
54	Development of an optimal sampling schedule for children receiving ketamine for shortâ€ŧerm procedural sedation and analgesia. Paediatric Anaesthesia, 2015, 25, 211-216.	0.6	8

#	Article	IF	CITATIONS
55	Community Surveillance of Respiratory Viruses Among Families in the Utah Better Identification of Germs-Longitudinal Viral Epidemiology (BIG-LoVE) Study. Clinical Infectious Diseases, 2015, 61, 1217-1224.	2.9	193
56	Pediatric vancomycin dosing: Trends over time and the impact of therapeutic drug monitoring. Journal of Clinical Pharmacology, 2015, 55, 212-220.	1.0	18
57	122Clinical and Microbiologic Characteristics of Pediatric Patients with Lemierre Syndrome. Open Forum Infectious Diseases, 2014, 1, S11-S11.	0.4	Ο
58	199Mandatory Antimicrobial Stewardship Program Review of Pediatric OPAT: Program Implementation and Results of Pilot Phase. Open Forum Infectious Diseases, 2014, 1, S89-S90.	0.4	0
59	Characteristics and publication patterns of obstetric studies registered in ClinicalTrials.gov. Journal of Clinical Pharmacology, 2014, 54, 432-437.	1.0	17
60	Rate of asthma trial outcomes reporting on ClinicalTrials.gov and in the published literature. Journal of Allergy and Clinical Immunology, 2014, 134, 1443-1446.	1.5	6
61	Preliminary Assessment of Zolpidem Pharmacokinetics in Pediatric Burn Patients. Therapeutic Drug Monitoring, 2014, 36, 295-301.	1.0	6
62	Intrapartum Magnesium Sulfate and the Potential for Cardiopulmonary Drug–Drug Interactions. Therapeutic Drug Monitoring, 2014, 36, 544-548.	1.0	6
63	Age-Specific Patterns of Influenza Activity in Utah: Do Older School Age Children Drive the Epidemic?. Journal of the Pediatric Infectious Diseases Society, 2014, 3, 163-167.	0.6	5
64	Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 71-79.	0.8	23
65	Evolution of interventional vancomycin trials in light of new antibiotic development in the USA, 1999–2012. International Journal of Antimicrobial Agents, 2014, 43, 215-222.	1.1	6
66	Pharmacokinetics and Pharmacodynamics of Antifungals in Children and their Clinical Implications. Clinical Pharmacokinetics, 2014, 53, 429-454.	1.6	37
67	Use of Methylxanthine Therapies for the Treatment and Prevention of Apnea of Prematurity. Paediatric Drugs, 2014, 16, 169-177.	1.3	47
68	Considerations in the Pharmacologic Treatment and Prevention of Neonatal Sepsis. Paediatric Drugs, 2014, 16, 67-81.	1.3	31
69	Alignment of United States funding for cardiovascular disease research with deaths, years of life lost, and hospitalizations. International Journal of Cardiology, 2014, 172, e19-e21.	0.8	4
70	A National Study of the Impact of Rapid Influenza Testing on Clinical Care in the Emergency Department. Journal of the Pediatric Infectious Diseases Society, 2014, 3, 112-118.	0.6	62
71	Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. Expert Review of Anti-Infective Therapy, 2014, 12, 1371-1388.	2.0	12
72	Development of levofloxacin inhalation solution to treat <i>Pseudomonas aeruginosa</i> in patients with cystic fibrosis. Therapeutic Advances in Respiratory Disease, 2014, 8, 13-21.	1.0	25

#	Article	IF	CITATIONS
73	Epidemiological Evaluation of Blood Culture Patterns among Neonates Receiving Vancomycin. Indian Journal of Microbiology, 2014, 54, 389-395.	1.5	3
74	Pharmacokinetics and Pharmacodynamics of Antibacterials, Antifungals, and Antivirals Used Most Frequently in Neonates and Infants. Clinical Pharmacokinetics, 2014, 53, 581-610.	1.6	37
75	Amikacin population pharmacokinetics among paediatric burn patients. Burns, 2014, 40, 311-318.	1.1	25
76	Use of quantitative 16S rRNA PCR to determine bacterial load does not augment conventional cerebrospinal fluid (CSF) cultures among children undergoing treatment for CSF shunt infection. Diagnostic Microbiology and Infectious Disease, 2014, 78, 188-195.	0.8	23
77	Maternal Magnesium Sulphate Exposure Predicts Neonatal Magnesium Blood Concentrations. Basic and Clinical Pharmacology and Toxicology, 2014, 114, 318-322.	1.2	15
78	Characteristics of antimicrobial studies registered in the USA through ClinicalTrials.Gov. International Journal of Antimicrobial Agents, 2013, 42, 161-166.	1.1	7
79	Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Pediatric Pulmonology, 2013, 48, 1047-1061.	1.0	51
80	Fluticasone Propionate Pharmacogenetics: CYP3A4*22 Polymorphism and Pediatric Asthma Control. Journal of Pediatrics, 2013, 162, 1222-1227.e2.	0.9	50
81	Reactive Intermediates Produced from the Metabolism of the Vanilloid Ring of Capsaicinoids by P450 Enzymes. Chemical Research in Toxicology, 2013, 26, 55-66.	1.7	38
82	Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium. Pediatric Pulmonology, 2013, 48, 1-7.	1.0	15
83	Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. Pediatric Pulmonology, 2013, 48, 211-220.	1.0	32
84	Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins. Pediatric Pulmonology, 2013, 48, 107-122.	1.0	46
85	Pneumococcal Meningitis in Children: Epidemiology, Serotypes, and Outcomes From 1997–2010 in Utah. Pediatrics, 2013, 132, 421-428.	1.0	47
86	Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary. Pediatric Pulmonology, 2013, 48, 525-537.	1.0	27
87	Population Pharmacokinetics of Intermittent Vancomycin in Children with Cystic Fibrosis. Pharmacotherapy, 2013, 33, 1288-1296.	1.2	41
88	Invasive Pneumococcal Disease in Infants Younger Than 90 Days Before and After Introduction of PCV7. Pediatrics, 2013, 132, e17-e24.	1.0	27
89	Seasonality of Acute Otitis Media and the Role of Respiratory Viral Activity in Children. Pediatric Infectious Disease Journal, 2013, 32, 314-319.	1.1	62
90	Cerebrospinal Fluid Pleocytosis in Febrile Infants 1–90 Days With Urinary Tract Infection. Pediatric Infectious Disease Journal, 2013, 32, 1024-1026.	1.1	17

#	Article	IF	CITATIONS
91	Bioequivalence and Bioavailability Clinical Trials: A Status Report from the National Institutes of Health ClinicalTrials.gov Registry. Journal of Bioequivalence & Bioavailability, 2013, 05, 244-247.	0.1	16
92	Laboratory-Confirmed Rotavirus Disease in Utah Children: Clinical and Economic Impact of Rotavirus Vaccination. Journal of the Pediatric Infectious Diseases Society, 2012, 1, 268-277.	0.6	3
93	The Changing Epidemiology of Invasive Pneumococcal Disease at a Tertiary Children's Hospital Through the 7-valent Pneumococcal Conjugate Vaccine Era. Pediatric Infectious Disease Journal, 2012, 31, 228-234.	1.1	44
94	Evolving Epidemiologic Characteristics of Invasive Group A Streptococcal Disease in Utah, 2002–2010. Clinical Infectious Diseases, 2012, 55, 479-487.	2.9	54
95	Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. Pediatric Pulmonology, 2012, 47, 1147-1158.	1.0	35
96	Evolution of the Epidemiology of Pneumococcal Disease Among Utah Children Through the Vaccine Era. Pediatric Infectious Disease Journal, 2011, 30, 1100-1103.	1.1	14
97	Population Pharmacokinetic and Pharmacodynamic Modeling of High-Dose Intermittent Ticarcillin-Clavulanate Administration in Pediatric Cystic Fibrosis Patients. Clinical Therapeutics, 2011, 33, 1844-1850.	1.1	12